Login to Your Account

Week in Washington

Monday, December 12, 2011

The FDA's latest proposed user fee structure for biosimilars will charge 10 percent of the new drug application fee, plus a development fee.

The U.S. Patent and Trademark Office and China's State Intellectual Property Office will expedite their patent examinations, which should allow applicants to obtain corresponding patents faster in each country.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription